ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)
CUSIP: 00166B105
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 132,496,020
- Total 13F shares
- 29,193,302
- Share change
- +1,323,706
- Total reported value
- $33,447,411
- Put/Call ratio
- 46%
- Price per share
- $1.13
- Number of holders
- 55
- Value change
- +$624,566
- Number of buys
- 24
- Number of sells
- 24
Quarterly Holders Quick Answers
What is CUSIP 00166B105?
CUSIP 00166B105 identifies ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00166B105:
Top shareholders of ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| LSV Associates, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,526,963
|
$61,575,751 | — | 13 Dec 2021 | |
| venBio Partners LLC |
13F
|
Company |
7.3%
|
9,699,925
|
$17,750,863 | — | 30 Sep 2025 | |
| Redmile Group, LLC |
13F
13D/G
|
Company |
8.5%
from 13D/G
|
3,332,983
|
$6,099,359 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
|
Company |
6%
|
3,188,196
|
$5,706,871 | +$861,071 | 17 Oct 2025 | |
| Almitas Capital LLC |
13F
|
Company |
1.9%
|
2,536,891
|
$4,642,511 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.2%
|
1,528,619
|
$2,797,372 | — | 30 Sep 2025 | |
| HBM Healthcare Investments (Cayman) Ltd. |
13D/G
|
— |
8.4%
|
4,500,000
|
$2,295,000 | +$547,266 | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.92%
|
1,220,825
|
$2,233,000 | — | 30 Sep 2025 | |
| TANG CAPITAL PARTNERS LP |
13D/G
|
TANG CAPITAL MANAGEMENT, LLC |
6.3%
|
3,296,883
|
$1,681,410 | $0 | 31 Dec 2024 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.6%
|
795,777
|
$1,456,272 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.54%
|
719,800
|
$1,317,234 | — | 30 Sep 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.49%
|
652,897
|
$1,194,802 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.46%
|
606,671
|
$1,110,208 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.4%
|
530,828
|
$971,415 | — | 30 Sep 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.38%
|
509,059
|
$931,578 | — | 30 Sep 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
3.4%
|
1,798,875
|
$917,426 | $0 | 29 Nov 2024 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.36%
|
474,781
|
$868,849 | — | 30 Sep 2025 | |
| Sophia Randolph |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
420,711
mixed-class rows
|
$840,334 | — | 14 Aug 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.34%
|
447,692
|
$819,277 | — | 30 Sep 2025 | |
| Jaume Pons |
3/4/5
|
PRESIDENT & CSO |
—
mixed-class rows
|
773,821
mixed-class rows
|
$666,412 | — | 19 Feb 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.27%
|
352,335
|
$645,030 | — | 30 Sep 2025 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.03%
|
41,000
|
$503,000 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.14%
|
180,416
|
$330,161 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.13%
|
172,570
|
$315,803 | — | 30 Sep 2025 | |
| Peter S. Garcia |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
mixed-class rows
|
201,516
mixed-class rows
|
$313,511 | — | 14 Aug 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.12%
|
164,499
|
$301,033 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.09%
|
113,063
|
$206,905 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.08%
|
111,928
|
$204,828 | — | 30 Sep 2025 | |
| BANK OF NOVA SCOTIA |
13F
|
Company |
0.08%
|
105,858
|
$193,720 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.07%
|
95,160
|
$174,143 | — | 30 Sep 2025 | |
| IEQ CAPITAL, LLC |
13F
|
Company |
0.07%
|
92,233
|
$168,786 | — | 30 Sep 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.07%
|
88,165
|
$161,000 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.06%
|
85,290
|
$156,081 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.05%
|
61,899
|
$113,275 | — | 30 Sep 2025 | |
| NAN FUNG TRINITY (HK) Ltd |
13F
|
Company |
0.03%
|
41,950
|
$76,769 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.03%
|
39,583
|
$72,436 | — | 30 Sep 2025 | |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC |
13F
|
Company |
0.03%
|
38,073
|
$69,674 | — | 30 Sep 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.03%
|
36,000
|
$65,880 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.02%
|
26,621
|
$48,716 | — | 30 Sep 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.02%
|
22,535
|
$41,000 | — | 30 Sep 2025 | |
| HC Advisors, LLC |
13F
|
Company |
0.02%
|
21,850
|
$39,986 | — | 30 Sep 2025 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.02%
|
20,572
|
$38,000 | — | 30 Sep 2025 | |
| Callan Family Office, LLC |
13F
|
Company |
0.01%
|
19,778
|
$36,194 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.01%
|
18,594
|
$34,027 | — | 30 Sep 2025 | |
| JSF Financial, LLC |
13F
|
Company |
0.01%
|
17,500
|
$32,025 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.01%
|
16,946
|
$31,011 | — | 30 Sep 2025 | |
| MONETA GROUP INVESTMENT ADVISORS LLC |
13F
|
Company |
0.01%
|
15,196
|
$27,809 | — | 30 Sep 2025 | |
| Point72 Asia (Singapore) Pte. Ltd. |
13F
|
Company |
0.01%
|
13,907
|
$25,449 | — | 30 Sep 2025 | |
| Lido Advisors, LLC |
13F
|
Company |
0.01%
|
13,220
|
$24,193 | — | 30 Sep 2025 | |
| Abel Hall, LLC |
13F
|
Company |
0.01%
|
12,598
|
$23,054 | — | 30 Sep 2025 |
Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q4 2025
As of 31 Dec 2025,
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) was held by
55 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,193,302 shares.
The largest 10 holders included
venBio Partners LLC, Redmile Group, LLC, MILLENNIUM MANAGEMENT LLC, Almitas Capital LLC, VANGUARD GROUP INC, Driehaus Capital Management LLC, ACADIAN ASSET MANAGEMENT LLC, UBS Group AG, TWO SIGMA ADVISERS, LP, and TWO SIGMA INVESTMENTS, LP.
This page lists
55
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
60
Q4 2025 holders
55
Holder diff
-5
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.